Radiopharm Theranostics Ltd
corporate_fare Company Profile
Radiopharm Theranostics Ltd (NASDAQ:RADX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 28 items for RADX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-30, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for RADX spans 6-K, 20-F, SCHEDULE 13D, 424B5.
Recent high-impact activity:
- Radiopharm Exits Quarter With A$7.5M Cash and Only 0.70 Quarters of Runway
- Radiopharm Draws $8M RDTI-Backed Advance From Rockford Capital
- Radiopharm Completes Productive FDA End-of-Phase 2 Meeting for RAD101, Advancing to Phase 3 Readiness
- Audited FY2026 Results Confirm A$56.3M Loss and Going Concern Warning for Radiopharm
- RAD101 Phase 2b Hits Primary Endpoint; Late-Breaking SNO26 Slot and FDA Meeting Set
Financial Snapshot
Short Interest & Short Volume
2.36 days to coverFINRA reported short interest of 141,864 shares in RADX as of the October 15, 2026 settlement, a 313.3% increase from the prior period — about 2.4 days to cover at its recent average daily volume. On October 30, 2026, 67.5% of RADX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for RADX, detected from its recent SEC filings · based on capital-structure filings through 2026-08-03.
Offering Priced at Deep Discount · Warrants Add Dilution Overhang
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
RADX files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.